CDEK
← All drugs Report issue

strontium-89

Small moleculeapproved

Approved

Jun 18, 1993

Strontium SR-89 is a radioactive isotope of strontium. Strontium-89 decays by beta emission with a half-life of 50.5 days. Beta-particles produced by radioactive decay penetrate tissues at a range of approximately 8 mm. Strontium SR-89 is used in medicine for the relief of bone pain in patients with painful skeletal metastases. Following intravenous injection, soluble strontium compounds behave like their calcium analogs, clearing rapidly from the blood and selectively localizing in bone mineral. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone. — NCATS

Clinical trial activity

15 trials · 23 clinical orgs · 2 marketing orgs

Phase 1
2
Phase 2
10
Phase 3
4
Phase 4
1

Earliest trial started Oct 1, 1992 (NCT00002503)

Timeline

1990s

  1. Jan 1, 1992

    Earliest Phase 3 Sponsor(trial)

  2. Jun 18, 1993

    Q Biomed — Earliest FDA Approval

  3. Jun 18, 1993

    Q Biomed — NDA Secondary Org

  4. Jun 18, 1993

    Q Biomed — NDA Organization

2000s

  1. Jan 1, 2002

    Earliest Phase 2 Sponsor(trial)

  2. Jan 6, 2003

    Bio Nucleonics — Marketing Organization

  3. Jan 6, 2003

    Q Biomed — Marketing Organization

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • Unspecified targetOTHER

    Unknown

Approval history

  • approvedPriority reviewJun 18, 1993

Chemistry & pharmacology

Loading structure…

SMILES

[Cl-].[Cl-].[Sr+2]
Mol. weight
158.53 g/mol
Chirality
Achiral Molecule
Inorganic
Yes
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • 89sr
  • 89sr
  • metastron
  • metastron
  • metastron
  • metastron
  • sms2pa
  • sms2pa
  • sms-2pa
  • sms-2pa
  • sr-89
  • sr-89
  • strontium
  • strontium
  • strontium-89
  • strontium-89
  • strontium-89
  • strontium-89 chloride
  • strontium-89 chloride
  • strontium-89 chloride
  • strontium (89sr) cation
  • strontium (89sr) chloride
  • strontium (89sr) chloride
  • strontium cation sr-89
  • strontium chloride
  • strontium chloride
  • strontium chloride
  • strontium chloride
  • strontium chloride, 85sr-labeled
  • strontium chloride (89sr)
  • strontium chloride (89sr)
  • strontium chloride, 89sr-labeled
  • strontium chloride, 90sr-labeled
  • strontium chloride, disodium salt
  • strontium chloride hexahydrate
  • strontium chloride hexahydrate
  • strontium chloride hexahydrate
  • strontium chloride monohydrate
  • strontium chloride sr 85
  • strontium chloride sr 89
  • strontium chloride sr 89
  • strontium chloride sr 89
  • strontium chloride sr-89
  • strontium chloride sr-89
  • strontium citrate
  • strontium citrate
  • strontium sr-89 cation

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05740488N/AFeb 28, 2023Southern Medical University
NCT05466812Phase 4Jul 13, 2022Chinese Academy of Medical Sciences
NCT02424214N/AJan 1, 2015Al Baraka Fertility Hospital, Banon IVF Center, Ibn Sina Hospital
NCT01870115Phase 1Aug 1, 2013Duquesne University
NCT01301677Phase 1Jan 1, 2011X-pert Med GmbH
NCT00954629Phase 3Jun 1, 2009MAC UK Neuroscience Ltd, SantoSolve AS, Smerud Medical Research Denmark
NCT00804375Phase 2Dec 1, 2008Aarhus University, SantoSolve AS, Smerud Medical Research Denmark
NCT00592098Phase 2Aug 1, 2007SantoSolve AS, Smerud Medical Research Denmark
NCT00365105Phase 3Jul 1, 2006Akron City Hospital, National Cancer Institute (NCI), NRG Oncology, Radiation Therapy Oncology Group
NCT00554918Phase 2Feb 1, 2005University of Birmingham
NCT00081159Phase 2Jul 1, 2004National Cancer Institute (NCI), University of Texas at Houston
NCT00156884Phase 2Aug 1, 2003Alberta Cancer Foundation, Amersham, The Prostate Cancer Research Foundation of Canada, University of Calgary
NCT00024167Phase 3Apr 1, 2002National Cancer Institute (NCI), University of Texas at Houston
NCT00080782Phase 2Feb 1, 2002National Cancer Institute (NCI), University of Texas at Houston
NCT00002503Phase 3Oct 1, 1992European Organisation for Research and Treatment of Cancer, Maastricht University
Showing 15 of 15 trials
Page 1 / 1

Organizations

Research & Development (23)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government4022002
SantoSolve ASFor profit3122007
Smerud Medical Research DenmarkFor profit3222007
University of Texas at HoustonAcademic/Hospital3322002
Aarhus UniversityAcademic/Hospital1012008
Akron City HospitalAcademic/Hospital1012006
Al Baraka Fertility HospitalAcademic/Hospital1012015
Alberta Cancer FoundationAcademic/Hospital1012003
AmershamFor profit1012003
Banon IVF CenterAcademic/Hospital1012015
Chinese Academy of Medical SciencesAcademic/Hospital1112022
Duquesne UniversityAcademic/Hospital1112013
European Organisation for Research and Treatment of CancerAcademic/Hospital1111992
Ibn Sina HospitalAcademic/Hospital1112015
Maastricht UniversityAcademic/Hospital1011992
MAC UK Neuroscience LtdFor profit1012009
NRG OncologyAcademic/Hospital1012006
Radiation Therapy Oncology GroupAcademic/Hospital1112006
Southern Medical UniversityAcademic/Hospital1112023
The Prostate Cancer Research Foundation of CanadaAcademic/Hospital1012003
23 organizations
Page 1 / 2

Marketing (4)

OrganizationOrg typeRelationshipDate
Bio NucleonicsFor profitMKTGJan 6, 2003
Q BiomedFor profitNDA2Jun 18, 1993
Q BiomedFor profitMKTGJan 6, 2003
Q BiomedFor profitNDAJun 18, 1993